enGene Therapeutics (ENGN) Cash from Operations (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Cash from Operations of 30501000.0 for Q2 2026, down 32.92% year-over-year from 45469138.37 in Q2 2025, and down 5.54% quarter-over-quarter from 28900000.0 in Q1 2026.
enGene Therapeutics (ENGN) Cash from Operations (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Cash from Operations for 4 consecutive years, with 30501000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Operations fell 32.92% year-over-year to 30501000.0; the TTM figure through Apr 2026 stood at 109997000.0 (down 45.9% YoY), while the FY2025 annual figure was 99239000.0, down 105.54% from the prior year.
- Cash from Operations eased to 30501000.0 in Q2 2026 per ENGN's latest filing, from 28900000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 4444000.0 in Q2 2023 and bottomed at 30501000.0 in Q2 2026.
- Historically, Cash from Operations has averaged 16547428.57 across 4 years, with a median of 16865000.0 in 2024.
- Annual changes were most pronounced in 2024 — Cash from Operations increased 1.63% — and 2025, when it slumped 256.97%.
- enGene Therapeutics' Cash from Operations stood at 6776000.0 in 2023, then tumbled by 188.78% to 19568000.0 in 2024, then dropped by 27.57% to 24962000.0 in 2025, then decreased by 22.19% to 30501000.0 in 2026.
- Business Quant data shows ENGN's Cash from Operations at 30501000.0 in Q2 2026, 28900000.0 in Q1 2026, and 24962000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | -30.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -30.50 Mn |
| Apr 30, 2026 | -30.50 Mn |
| Jan 31, 2026 | -28.90 Mn |
| Jan 31, 2026 | -28.90 Mn |
| Oct 31, 2025 | -24.96 Mn |
| Oct 31, 2025 | -24.96 Mn |
| Jul 31, 2025 | -25.63 Mn |
| Jul 31, 2025 | -25.63 Mn |
| Apr 30, 2025 | -22.95 Mn |
| Apr 30, 2025 | -22.95 Mn |
| Jan 31, 2025 | -25.70 Mn |
| Jan 31, 2025 | -25.70 Mn |
| Oct 31, 2024 | -19.57 Mn |
| Oct 31, 2024 | -19.57 Mn |
| Jul 31, 2024 | -7.18 Mn |
| Jul 31, 2024 | -7.18 Mn |
| Apr 30, 2024 | -14.16 Mn |
| Apr 30, 2024 | -14.16 Mn |
| Jan 31, 2024 | -7.37 Mn |
| Jan 31, 2024 | -7.37 Mn |